← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro + VRd

daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide and dexamethasone · Janssen Biotech

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.

LAMPGEN ANALYSIS

Why it matters

This adds a CD38 antibody to an established three-drug backbone for transplant-ineligible patients. The FDA distinguishes transplant ineligibility from patients who declined transplant in the study.

What research teams should watch

Record the reason for transplant ineligibility, then coordinate route, cycle timing and safety monitoring across four agents.

PRIMARY RECORDS

Sources